Brief: Dyadic Provides Phase 1 Clinical Trial Update For Its Dyai-100 Covid-19 Recombinant Protein Rbd Booster Vaccine Candidate

Dyadic International

07/03/2023 13:40

March 7 (Reuters) - Dyadic International Inc  DYAI.O :
    * DYADIC PROVIDES PHASE 1 CLINICAL TRIAL UPDATE FOR ITS
DYAI-100
COVID-19 RECOMBINANT PROTEIN RBD BOOSTER VACCINE CANDIDATE
    * DYADIC INTERNATIONAL INC - DOSING OF ALL PATIENTS WAS
COMPLETED
AT END OF FEBRUARY
    * DYADIC INTERNATIONAL INC - NO SERIOUS ADVERSE EVENTS
(SAE'S)
HAVE BEEN REPORTED
    * DYADIC INTERNATIONAL INC - PHASE 1 CLINICAL INITIAL SAFETY
AND
ANTIBODY RESPONSE UPDATE EXPECTED IN Q2, 2023

Source text for Eikon:  ID:nGNXcg1Crm 
Further company coverage:  DYAI.O 

 ((Reuters.Briefs@thomsonreuters.com;))